生姜对COVID-19所致严重急性呼吸综合征患者临床表现及辅助检查特征影响的随机对照试验方案结构化摘要
本研究为单中心、随机、双盲、安慰剂对照平行组临床试验,计划纳入84例PCR确诊、影像学显示中度肺炎的SARS-CoV-2感染住院患者,比较标准治疗联合生姜制剂(Vomigone® 1000 mg每日三次,共7天)与联合安慰剂对临床症状恢复率及辅助检查特征(血小板减少、淋巴细胞减少、C反应蛋白)的影响。主要结局为随机化7天内临床症状和辅助检查特征的恢复率,次要结局包括改善时间及严重不良事件发生率。
要点
- 生姜组在标准治疗基础上加用Vomigone® 1000 mg每日三次,疗程7天。
- 主要结局为7天内发热、干咳、乏力、胃肠道症状及血小板减少、淋巴细胞减少、CRP的恢复率。
- 计划随机84例(每组42例),采用区组随机1:1分配,所有参与者和研究者均设盲。
核心结论
- 该试验旨在评估生姜联合标准治疗对中度COVID-19患者临床症状和辅助检查特征的疗效,目前仅为研究方案摘要,尚未报告结果。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照、平行组临床试验。
- 计划随机84例符合纳入排除标准的PCR确诊SARS-CoV-2感染住院患者,每组42例,按1:1区组随机分配。
- 纳入标准包括年龄≥18岁(体重≥35 kg)、住院≤48小时、影像学显示中度肺炎且签署知情同意。
- 排除标准包括特定基础疾病、使用华法林/SSRIs/MAOIs/利尿剂/糖皮质激素/抗心律失常药、重度和危重型肺炎、生姜过敏史及妊娠哺乳期。
关键数值与推荐
- 干预组:标准治疗联合生姜制剂Vomigone® 1000 mg每日三次,共7天。
- 对照组:标准治疗联合Vomigone®类似安慰剂片,每次两片每日三次,共7天。
- 主要结局:随机化7天内发热、干咳、乏力、胃肠道症状的恢复率及血小板减少、淋巴细胞减少、C反应蛋白的恢复率。
- 次要结局:随机化7天内临床和辅助检查特征改善时间及严重不良事件发生率。
临床怎么用
- 该方案为生姜辅助治疗中度COVID-19的临床研究设计,结果未出前不构成临床用药推荐。
局限性
- 本文仅为研究方案摘要,无疗效和安全性结果数据。
- 单中心设计、样本量84例,可能限制结果外推性。
- 随访期仅7天,无法评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill. TRIAL DESIGN: This is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design. PARTICIPANTS: Inclusion criteria: 1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran 2. Age ≥18 years (weight ≥35 kg) 3. Hospitalized ≤48 hours 4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PCR)) 5. Moderate pneumonia and lung involvement in imaging 6. Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm Exclusion criteria: 1. Underlying diseases, including heart disease, chronic hypertension, severe renal failure, severe liver failure, and thyroid disorders 2. Use of warfarin, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), diuretics, corticosteroids, and antiarrhythmic drugs 3. Severe and critical pneumonia 4. History of known allergy to Ginger 5. Pregnancy and breastfeeding INTERVENTION AND COMPARATOR: Intervention group: The standard treatment regimen for COVID-19 along with Ginger-based herbal tablets (Vomigone ®, Dineh Pharmaceutical Company, Iran) at a dose of 1000 mg three times a day for a period of seven days. CONTROL GROUP: The standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education's protocol, along with Vomigone-like placebo tablets (Dineh Pharmaceutical Company, Iran) at a dose of two tablets three times a day for a period of seven days. MAIN OUTCOMES: The primary outcome is recovery rate of clinical symptoms, including fever, dry cough, tiredness, and GI symptoms as well as paraclinical features, including thrombocytopenia, lymphocytopenia, and C-reactive protein within seven days of randomization. Time to improvement of clinical and paraclinical features along with the incidence of serious adverse events are the secondary outcomes within seven days of randomization. RANDOMIZATION: An interactive web-based system will be used to allocate eligible participants, based on the inclusion and exclusion criteria, to one of the two study arms (in a 1:1 ratio) using block randomization. BLINDING (MASKING): All study participants, research coordinators, clinicians, nurses, and investigators will be blinded to the group assignment. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 84 participants will be randomized into two groups of 42 patients. TRIAL STATUS: The protocol is Version 1.0, May 23, 2020. Recruitment began July 21, 2020, and is anticipated to be completed by October 30, 2020. TRIAL REGISTRATION: This clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20200506047323N1 ". Registration date is 23 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Safa O, Hassaniazad M, Farashahinejad M, et al. Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33036662. doi:10.1186/s13063-020-04765-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。